1. Home
  2. Directory
  3. Louisiana
  4. Baton Rouge
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1235525643

KATIE VERON TAYLOR M.D.
Prescription History 1235525643
Internal Medicine - Infectious Disease in Baton Rouge, LA

NPI Status: Active since April 13, 2015

Contact Information

5246 BRITTANY DR
BATON ROUGE, LA
ZIP 70808
Phone: (225) 767-4300

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KATIE VERON TAYLOR M.D., an active Infectious Disease specialist practicing in Baton Rouge, LA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 49 documented patient claims. Among these therapy options, the most frequently utilized medication is Meropenem, which accounts for 21 claims alone.

Medication Index

A
C
M
No matching medications currently found on file.

Amikacin Sulfate

Generic Formulation: Amikacin SulfateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 104
LA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.8
Peer Average Days Supply166
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,161.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$72.58

State Avg Cost Per Claim

$103.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

Therapeutic Applications

This medication is used to prevent or treat a wide variety of bacterial infections. Amikacin belongs to a class of drugs known as aminoglycoside antibiotics. It works by stopping the growth of bacteria.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 83
LA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply126
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,355.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$279.61

State Avg Cost Per Claim

$51.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Meropenem

Generic Formulation: MeropenemSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 147
LA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.9
Peer Average Days Supply129
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,933.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$377.80

State Avg Cost Per Claim

$271.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.

Therapeutic Applications

Meropenem is used to treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KATIE VERON TAYLOR M.D. provides transparency into local medical care patterns within Baton Rouge, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.